10062929Implementation & digitalisation of Process Analytical Technologies to increase productivity, support rapid release and reduce costs of goods in industrial scale Cell & Gene Therapy (CGT) manufacturingClosedCollaborative R&DInnovate UKIn response to the Innovate UK (IUK) Digitalisation and Automation of Medicines R&D and Manufacture grant call, Autolomous and the Cell and Gene Therapy Catapult (CGTC) are proposing a collaboration that aims to enable key stakeholders in the CGT industry (namely therapy developers) to make meaningful progress towards improving manufacturing productivity and removing key bottlenecks through automation and digitisation. This will consequently reduce costs of CGT products and increase patient access to these life-changing therapies. Advanced Therapy Medicinal Products (ATMP), especially CGTs, are manufactured in per patient or in small batches requiring complex, semi-manual, labour intensive and time consuming manufacturing processes. A consequence of this is high drug product (DP) costs as demonstrated by currently available commercial CGT products ($400,000 to $3.5m per patient). Autolomous is the market leading developer of critical manufacturing management systems for CGTs. Autolomous internationally deploys fully integrated, digitized and automated supply chain software solutions. These solutions utilize emerging technologies such as Ledger Technology (LT) and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. CGTC is an independent innovation and technology organisation committed to the advancement of CGTs with a vision of a thriving industry delivering life changing advanced therapies to the world. The project aims to demonstrate the digital introduction of novel Process Analytical Technologies (PAT) into an industrial scale CGT manufacturing process within an industrial manufacturing facility. The project outputs will serve as blueprints outlining the key challenges and considerations of introducing new technologies into an industrial manufacturing environment, and the benefits of leveraging digitalisation for the purpose of automation of data collection to enable streamlined batch certification and release. The overall objective is to help ATMP developers and PAT providers mitigate the risk, reduce the costs and expedite the process of introducing and integrating systems and/or new technologies.